查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088975

泌尿生殖系統藥物市場：2026-2032年全球市場預測（依藥物類別、適應症、給藥途徑、最終用戶和分銷管道分類）

Genitourinary Drugs Market by Drug Class, Indication, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，泌尿生殖系統藥物市場將成長至 558.8 億美元，複合年成長率為 4.32%。

主要市場統計數據
基準年 2025 415.4億美元
預計年份：2026年 433.3億美元
預測年份 2032 558.8億美元
複合年成長率 (%) 4.32%

泌尿生殖系統藥物市場涵蓋治療與尿道感染、良性前列腺增生、膀胱過動症過動症、勃起功能障礙和子宮內膜異位症相關的泌尿生殖系統症狀，以及治療包括前列腺癌、膀胱癌和腎癌在內的泌尿器官系統癌症。人口老化、篩檢技術的改進、專科藥物使用量的增加、抗生素抗藥性以及支付方對藥物價值的審查等因素也影響著市場趨勢。行業領導者透過利用臨床差異化優勢、長期安全性數據、患者依從性以及支持快速獲得保險覆蓋的證據，在包括醫院、零售藥局、專科藥房和公共採購在內的各種管道展開競爭。

將重塑泌尿生殖醫學的變革性變化

醫學治療的重點正從控制症狀轉向精準醫療、預防和疾病修正治療。在泌尿系統腫瘤領域，雄性激素受體路徑抑制劑、免疫查核點抑制劑、抗體藥物複合體、標靶治療和放射性配體療法正在改變前列腺癌、膀胱癌和腎癌的治療順序。在非腫瘤領域，BETA3促效劑、改良的α阻斷劑策略、5型磷酸二酯酶抑制劑和聯合治療正在提高用藥的便利性和患者的用藥依從性。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在藥物發現、臨床開發、商業化和藥物安全監測的各個階段產生累積影響。在前列腺癌、膀胱癌和腎癌領域，AI 驅動的標靶識別、分子篩檢、生物標記發現和影像分析尤其重要，因為患者分層能夠提高臨床試驗和治療方案的效率。包括美國食品藥物管理局(FDA) 在內的監管機構報告稱，在藥物開發申報中擴大使用 AI 和機器學習技術，反映出 AI 和機器學習技術在生命科學領域的應用日益廣泛。

全球市場的關鍵區域洞察

隨著中國和印度擴大學名藥、生物相似藥、抗癌藥物和醫院專科服務的覆蓋範圍，亞太地區正成為重點市場；與此同時，日本、韓國和澳洲因人口老化而對泌尿系統和癌症治療的需求不斷成長。該地區龐大的患者群體、不斷提升的診斷能力以及日益擴大的國內製藥生產，都加劇了治療的可及性和競爭。

針對特定群體的關鍵策略定位洞察

隨著印尼、越南、泰國、馬來西亞和菲律賓擴大醫療保險覆蓋範圍、拓展零售藥局網路並加強本地生產夥伴關係，東協市場的重要性日益凸顯。打入市場策略必須充分考慮各國獨特的報銷體系、醫師教育程度和價格敏感度。在海灣合作理事會（GCC）國家，由於人均醫療費用支出高企且政府主導採購，專科護理、癌症治療以及處方藥清單的最佳化成為優先事項，因此做好競標準備和價值證明至關重要。

市場優先排序的關鍵國家洞察

美國在泌尿生殖系統癌症專科治療的推廣、臨床試驗活動以及FDA核准創新方面處於主導，而加拿大則強調循證報銷和全國範圍內的價格管控。墨西哥和巴西是拉丁美洲重要的准入市場，公共採購、私人保險和學名藥都會影響藥物的普及。在歐洲，英國、德國、法國、義大利和西班牙都面臨人口老化問題，但同時擁有強大的泌尿系統網路，然而由於各國醫療技術評估流程的差異，對實證醫學和定價的期望也各不相同。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床證據，包括直接比較數據、患者報告結局、長期安全性數據和真實世界療效。在泌尿系統腫瘤領域，企業需要生物標記策略、定序證據以及面向支付方的增值文件。在以感染疾病為重點的產品組合中，必須將合理使用抗生素、快速診斷標準化和抗藥性監測納入產品上市計畫。

調查方法和資料的檢驗

本執行摘要基於系統的二手研究方法，使用公開的權威二手資料，包括來自世界衛生組織、美國疾病控制與預防中心、美國食品藥品監督管理局、歐洲藥品管理局、歐洲疾病預防控制中心、美國國立衛生研究院、美國國家癌症研究所、GLOBOCAN 2022、經濟合作暨發展組織、世界銀行和聯合國的人口統計研究途徑評估文件，以及臨床調查註冊的學術資訊期刊

結論與策略展望

受人口結構變化、癌症治療創新、感染控制需求以及新興經濟體醫療服務可近性提高等因素的推動，泌尿生殖系統藥物市場持續成長。儘管泌尿器官系統癌症、復發性尿道感染、良性前列腺增生和膀胱過動症疾病仍將滿足廣泛的治療需求，但由於保險公司的期望和抗生素抗藥性問題，對實證醫學證據的要求將更高。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：泌尿生殖系統藥物市場：依藥物類別分類

  • 抗生素
    • 抗生素
    • 抗真菌藥物
    • 抗病毒藥物
    • 驅蟲
  • α-腎上腺素受體阻斷劑
  • 5α-還原酶抑制劑
    • 1型抑制劑
    • 2型抑制劑
  • 5型磷酸二酯酶抑制劑
  • 泌尿道疼痛緩解劑
  • 荷爾蒙療法
    • 雄激素
    • 雌激素
    • 黃體素
  • 烷化劑和細胞毒性藥物

第8章：泌尿生殖系統藥物市場：依適應症分類

  • 尿道感染
    • 單純性尿道感染
    • 複雜性尿道感染
    • 復發性尿道感染
  • 良性攝護腺增生
  • 勃起功能障礙
  • 女性性功能障礙
  • 尿失禁
  • 膀胱過動症
  • 性行為感染傳染病
    • 披衣菌感染
    • 淋病
    • 梅毒
    • 滴蟲病
  • 膀胱疾病

第9章：泌尿生殖系統藥物市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 肌肉內部
    • 皮下
  • 口服
    • 藥片
    • 膠囊
    • 口服懸浮液
  • 外用
    • 奶油
    • 凝膠

第10章：泌尿生殖系統藥物市場：依最終用戶分類

  • 專科診所
    • 泌尿系統診所
    • 婦科診所
    • 腎臟病診所
  • 居家照護環境
  • 醫院
  • 研究和學術機構
  • 門診手術中心

第11章：泌尿生殖系統藥物市場：依分銷管道分類

  • 離線
  • 線上

第12章：泌尿生殖系統藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：泌尿生殖系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：泌尿生殖系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc.
  • GSK plc
  • Johnson & Johnson
  • Kissei Pharmaceutical Co. Ltd.
  • Melinta Therapeutics LLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UroGen Pharma Ltd
  • Viatris Inc.
Product Code: MRR-ED54C46E88A6

The Genitourinary Drugs Market is projected to grow by USD 55.88 billion at a CAGR of 4.32% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.54 billion
Estimated Year [2026] USD 43.33 billion
Forecast Year [2032] USD 55.88 billion
CAGR (%) 4.32%

The genitourinary drugs market spans therapies for urinary tract infections, benign prostatic hyperplasia, overactive bladder, erectile dysfunction, endometriosis-related urogenital symptoms, and urologic cancers, including prostate, bladder, and kidney cancer. Market momentum is also being shaped by population aging, improved screening, broader use of specialty medicines, antimicrobial resistance, and payer scrutiny over value. Industry leaders are competing on clinical differentiation, durable safety data, patient adherence, and evidence that supports faster formulary access across hospital, retail, specialty, and public procurement channels.

Transformative Shifts Reshaping Genitourinary Care

The landscape is shifting from symptom control toward precision, prevention, and disease-modifying care. In urologic oncology, androgen receptor pathway inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, targeted therapies, and radioligand approaches are changing treatment sequencing for prostate, bladder, and kidney cancers. In non-oncology segments, beta-3 agonists, improved alpha-blocker strategies, phosphodiesterase type 5 inhibitors, and combination regimens are advancing convenience and adherence.

A second structural shift is the rising importance of stewardship and evidence-based prescribing. Antimicrobial resistance has made uncomplicated and recurrent urinary tract infection management more complex, pushing drug developers and health systems toward rapid diagnostics, narrower-spectrum agents, non-antibiotic prevention, and real-world surveillance. At the same time, regulatory agencies and payers increasingly expect comparative data, patient-reported outcomes, and durable safety evidence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across discovery, clinical development, commercialization, and pharmacovigilance. AI-enabled target identification, molecular screening, biomarker discovery, and imaging analytics are particularly relevant in prostate, bladder, and kidney cancer, where patient stratification can improve trial efficiency and treatment selection. Regulators, including the U.S. FDA, have reported growing use of AI and machine learning in drug development submissions, reflecting broader adoption across the life sciences sector.

In genitourinary drugs, AI can also improve trial site selection, predict recruitment bottlenecks, analyze real-world evidence from electronic health records, and identify safety signals earlier. The strongest near-term value will come from governed AI models that combine clinical validity, transparent data provenance, bias monitoring, and compliance with privacy regulations such as HIPAA and GDPR.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming a high-priority arena as China and India expand access to generics, biosimilars, oncology medicines, and hospital-based specialty care, while Japan, South Korea, and Australia drive demand for aging-related urology and cancer treatments. The region's large patient base, increasing diagnostic capacity, and expanding domestic pharmaceutical manufacturing are strengthening both treatment access and competitive intensity.

North America remains a leading innovation and revenue center because of FDA pathways, high oncology adoption, strong specialty pharmacy infrastructure, and substantial R&D investment. Europe benefits from EMA oversight, mature reimbursement systems, and aging populations, while the EU Health Technology Assessment Regulation is increasing the importance of comparative clinical evidence. Latin America, led by Brazil and Mexico, is expanding access through public formularies and generics, although affordability and reimbursement variability remain constraints. The Middle East, especially GCC markets, is investing in specialty care and centralized procurement, while Africa's opportunity is anchored in access expansion, infection management, diagnostics, and reliable supply of essential genitourinary medicines.

Key Group Insights for Strategic Positioning

ASEAN markets are gaining relevance as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines expand healthcare coverage, retail pharmacy reach, and local manufacturing partnerships. Access strategies must account for country-specific reimbursement, physician education, and pricing sensitivity. GCC countries, supported by high per-capita health spending and government-led procurement, are prioritizing specialty care, oncology access, and formulary discipline, making tender readiness and value evidence essential.

The European Union is advancing harmonized assessment and stronger evidence requirements, increasing the need for robust comparative outcomes and real-world data. BRICS countries combine large patient populations with growing domestic production, creating opportunities for localized manufacturing, generics, and differentiated specialty launches. G7 markets remain the strongest centers for premium innovation, clinical research, and early adoption, while NATO-aligned supply chain resilience initiatives are elevating attention to pharmaceutical security, active ingredient sourcing, and continuity planning.

Key Country Insights for Market Prioritization

The United States leads in specialty genitourinary oncology uptake, clinical trial activity, and FDA-approved innovation, while Canada emphasizes evidence-based reimbursement and pan-Canadian pricing discipline. Mexico and Brazil are important Latin American access markets where public procurement, private insurance, and generics shape adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging demographics with strong urology networks, but national health technology assessment processes create distinct evidence and pricing expectations.

Russia remains influenced by localization policies and public procurement dynamics. China is scaling oncology access through regulatory reform, volume-based procurement, and domestic innovation, while India's strength lies in generics, cost-efficient manufacturing, and high-volume treatment needs. Japan faces significant aging-related demand and values safety, quality, and reimbursement discipline; South Korea is strong in digital health and clinical research; and Australia offers a transparent reimbursement environment supported by established cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, including head-to-head data, patient-reported outcomes, durable safety findings, and real-world effectiveness. In urologic oncology, companies need biomarker strategies, sequencing evidence, and payer-ready value dossiers. In infection-focused portfolios, antimicrobial stewardship, rapid diagnostic alignment, and resistance surveillance should be embedded into launch planning.

Commercial strategies should be localized by reimbursement model, procurement pathway, and care setting. Manufacturers can improve resilience by diversifying active pharmaceutical ingredient sourcing, strengthening pharmacovigilance, investing in adherence support, and partnering with health systems on data generation. AI adoption should focus on validated use cases with measurable impact on R&D productivity, trial execution, medical affairs, and post-market safety.

Research Methodology and Data Validation

This executive summary is based on a structured secondary research approach using publicly available and authoritative sources, including WHO, CDC, FDA, EMA, ECDC, NIH, National Cancer Institute, GLOBOCAN 2022, OECD, World Bank, United Nations demographic datasets, peer-reviewed journals, clinical trial registries, regulatory labels, and health technology assessment documents.

Insights were triangulated across epidemiology, regulatory developments, reimbursement trends, clinical innovation, patent activity, and regional healthcare infrastructure. Data points were used only where supported by credible sources, and qualitative conclusions were validated through consistency checks across multiple references to ensure relevance for strategic planning in the genitourinary drugs market.

Conclusion and Strategic Outlook

The genitourinary drugs market is advancing through a combination of demographic demand, oncology innovation, infection-control needs, and expanding access in emerging economies. Urologic cancers, recurrent urinary tract infections, benign prostatic hyperplasia, and overactive bladder will continue to support broad therapeutic demand, while payer expectations and antimicrobial resistance will raise the bar for evidence.

Organizations that combine clinical differentiation, responsible stewardship, regional access expertise, AI-enabled execution, and resilient supply chains will be best positioned. The market's next phase will reward stakeholders that can deliver measurable patient outcomes while navigating increasingly complex regulatory, pricing, and procurement environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genitourinary Drugs Market, by Drug Class

  • 7.1. Antimicrobials
    • 7.1.1. Antibiotics
    • 7.1.2. Antifungals
    • 7.1.3. Antivirals
    • 7.1.4. Antiparasitics
  • 7.2. Alpha Adrenergic Blockers
  • 7.3. 5 Alpha Reductase Inhibitors
    • 7.3.1. Type 1 Inhibitors
    • 7.3.2. Type 2 Inhibitors
  • 7.4. Phosphodiesterase Type 5 Inhibitors
  • 7.5. Urinary Analgesics
  • 7.6. Hormonal Therapies
    • 7.6.1. Androgens
    • 7.6.2. Estrogens
    • 7.6.3. Progestins
  • 7.7. Alkylating & Cytotoxic Agents

8. Genitourinary Drugs Market, by Indication

  • 8.1. Urinary Tract Infections
    • 8.1.1. Uncomplicated UTI
    • 8.1.2. Complicated UTI
    • 8.1.3. Recurrent UTI
  • 8.2. Benign Prostatic Hyperplasia
  • 8.3. Erectile Dysfunction
  • 8.4. Female Sexual Dysfunction
  • 8.5. Urinary Incontinence
  • 8.6. Overactive Bladder
  • 8.7. Sexually Transmitted Infections
    • 8.7.1. Chlamydia
    • 8.7.2. Gonorrhea
    • 8.7.3. Syphilis
    • 8.7.4. Trichomoniasis
  • 8.8. Bladder Disorders

9. Genitourinary Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Intramuscular
    • 9.1.3. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Tablets
    • 9.2.2. Capsules
    • 9.2.3. Oral Suspensions
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Gels

10. Genitourinary Drugs Market, by End User

  • 10.1. Specialty Clinics
    • 10.1.1. Urology Clinics
    • 10.1.2. Gynecology Clinics
    • 10.1.3. Nephrology Clinics
  • 10.2. Homecare Settings
  • 10.3. Hospitals
  • 10.4. Research & Academic Institutes
  • 10.5. Ambulatory Surgical Centers

11. Genitourinary Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Genitourinary Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Genitourinary Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genitourinary Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Aspen Pharmacare Holdings Limited
  • 16.4. Astellas Pharma Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Aurobindo Pharma Limited
  • 16.7. Bayer AG
  • 16.8. Boehringer Ingelheim International GmbH
  • 16.9. Boston Scientific Corporation
  • 16.10. Bristol-Myers Squibb Company
  • 16.11. Cipla Limited
  • 16.12. Dr. Reddy's Laboratories Limited
  • 16.13. Eli Lilly and Company
  • 16.14. F. Hoffmann-La Roche Ltd
  • 16.15. Gilead Sciences Inc.
  • 16.16. GSK plc
  • 16.17. Johnson & Johnson
  • 16.18. Kissei Pharmaceutical Co. Ltd.
  • 16.19. Melinta Therapeutics LLC
  • 16.20. Merck & Co. Inc.
  • 16.21. Novartis AG
  • 16.22. Pfizer Inc.
  • 16.23. Sanofi S.A.
  • 16.24. Sun Pharmaceutical Industries Limited
  • 16.25. Takeda Pharmaceutical Company Limited
  • 16.26. Teva Pharmaceutical Industries Ltd.
  • 16.27. UroGen Pharma Ltd
  • 16.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENITOURINARY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL URINARY ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL URINARY ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINARY ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANDROGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANDROGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANDROGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ESTROGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ESTROGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ESTROGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGESTINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROGESTINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGESTINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLICATED UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPLICATED UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPLICATED UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RECURRENT UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RECURRENT UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RECURRENT UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHLAMYDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHLAMYDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHLAMYDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GONORRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GONORRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GONORRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SYPHILIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYPHILIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SYPHILIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRICHOMONIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRICHOMONIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRICHOMONIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BLADDER DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLADDER DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLADDER DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL UROLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL UROLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL UROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. GCC GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. GCC GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 277. GCC GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 281. GCC GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 282. GCC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. GCC GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. G7 GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. G7 GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 317. G7 GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. G7 GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 322. G7 GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 323. G7 GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. G7 GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 325. G7 GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 326. G7 GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 327. G7 GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. G7 GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 329. G7 GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. NATO GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. NATO GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 332. NATO GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 333. NATO GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 334. NATO GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 335. NATO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 336. NATO GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 337. NATO GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 338. NATO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. NATO GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 340. NATO GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 341. NATO GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 342. NATO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. NATO GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 344. NATO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 361. CANADA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 363. CANADA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 364. CANADA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA